Ticker League

Latest period

$2.98B

YoY change

+11.2%

5Y CAGR

Peak year (2025)

$3.06B

Operating Cash Flow history chart for CoreWeave (CRWV) from 2022 to 2025

Latest: $3.06B

Operating Cash Flow growth chart for CoreWeave (CRWV) from 2022 to 2025

Latest: +11.2%

Operating Cash Flow history table for CoreWeave (CRWV) from 2022 to 2025

  • 2025$3.06B+11.2%
  • 2024$2.75B+50.0%
  • 2023$1.83B+201290.1%
  • 2022$910.00K

Operating Cash Flow values are taken from CoreWeave's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Operating Cash Flow at CoreWeave (CRWV)

Operating Cash Flow for CoreWeave (CRWV): headline value $2.98B · YoY +11.2%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, CoreWeave (CRWV) reported operating cash flow of $3.06B – grew 11.2% year-over-year.

CoreWeave Operating Cash Flow by Year

CoreWeave Operating Cash Flow 2025: $3.06B

CoreWeave posted operating cash flow of $3.06B in 2025, grew 11.2% from 2024. This figure represents the highest annual value in the available history.

CoreWeave Operating Cash Flow 2024: $2.75B

In 2024, CoreWeave reported operating cash flow of $2.75B, surged 50.0% from 2023.

CoreWeave Operating Cash Flow 2023: $1.83B

CoreWeave operating cash flow in 2023 was $1.83B, surged 201290.1% from 2022.

CoreWeave Operating Cash Flow 2022: $910.00K

CoreWeave operating cash flow in 2022 was $910.00K.

See more financial history for CoreWeave (CRWV).

Sector peers by Operating Cash Flow

Technology peers of CoreWeave (CRWV), ranked by their latest operating cash flow

Frequently asked questions

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation